KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Shares Outstanding (Weighted Average) (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed 0.0% to $2.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.4 billion for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $2.4 billion in Q4 2025 for Johnson & Johnson, roughly flat from $2.4 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $2.6 billion in Q1 2021 to a low of $2.4 billion in Q2 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $2.5 billion across 5 years, with a median of $2.6 billion in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): decreased 7.57% in 2024 and later grew 0.04% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2.6 billion in 2021, then dropped by 0.13% to $2.6 billion in 2022, then fell by 3.63% to $2.5 billion in 2023, then dropped by 4.98% to $2.4 billion in 2024, then increased by 0.0% to $2.4 billion in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for JNJ at $2.4 billion in Q4 2025, $2.4 billion in Q3 2025, and $2.4 billion in Q2 2025.